Chemoprevention of hepatocarcinogenesis with dietary isoprenic derivatives: Cellular and molecular aspects

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1173-1190

  Ong, Thomas Prates ^a   Cardozo, Mônica Testoni ^a   de Conti, Aline ^a   Moreno, Fernando Salvador ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bioactive food components; Cellular targets; Chemoprevention; Dietary isoprenic derivatives; Liver cancer; Molecular targets

Indexed keywords

ALITRETINOIN; ALPHA CAROTENE; BETA CAROTENE; BETA IONONE; CONNEXIN 43; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DITERPENE; FARNESOID X RECEPTOR; FARNESOL; GERANIOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENE; LIMONENE; LYCOPENE; MYC PROTEIN; PERILLYL ALCOHOL; PREGNANE X RECEPTOR; RETINOIC ACID; RETINOL; RHO FACTOR; SQUALENE; TERPENE; XANTHOPHYLL;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL COMMUNICATION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DIET THERAPY; DNA METHYLATION; FOOD; GENE EXPRESSION; HUMAN; LEAFY VEGETABLE; LIVER CARCINOGENESIS; NONHUMAN; PARTIAL HEPATECTOMY; UPREGULATION;

EID: 84872510778     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096112091173     Document Type: Article

References (132)

1. Benowitz, S. Liver cancer biomarkers struggling to succeed. J. Natl. Cancer Inst. 2007, 99, 590-591.
2. Sell, S. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003, 63, 7553-7562.
3. Bruix, J.; Boix, L.; Sala, M.; Llovet, J. M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5, 215-219.
4. Llovet, J. M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet 2003, 362, 1907-1917.
5. Xie, B.; Wang, D. H.; Spechler, S. J. Sorafenib for treatment of hepatocellular carcinoma: A systematic review. Dig. Dis. Sci. 2012 Mar 27. doi: 10.1007/s10620-012-2136-1.
6. Kensler, T. W.; Quian, G. S.; Chen, J. G.; Groopman, J. D. Translational strategies for cancer prevention in liver. Nat. Rev. Cancer 2003, 3, 321-329.
7. Sporn, M. B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976, 36, 2699-2702.
8. Wattenberg, L. W. Chemoprevention of cancer. Cancer Res. 1985, 45, 1-8.
9. Su, Q.; Bannasch, P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol. Pathol. 2003, 31, 126-133.
10. Andersen, J. B.; Loi, R.; Perra, A.; Factor, V. M.; Ledda-Columbano, G. M.; Columbano, A.; Thorgeirsson, S. S. Progenitorderived hepatocellular carcinoma model in the rat. Hepatology 2010, 51, 1401-1409.
11. Frau, M.; Simile, M. M.; Tomasi, M. L.; Demartis, M. I.; Daino, L.; Seddaiu, M. A.; Brozzetti, S.; Feo, C. F.; Massarelli, G.; Solinas, G.; Feo, F.; Lee, J. S.; Pascale, R. M. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell. Oncol. (Dordr) 2012, Mar 21. doi: 10.1007/s13402-011-0067.
12. Surh, Y. J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768-780.
13. Milner, J. A.; McDonald, S. S.; Anderson, D. E.; Greenwald, P. Molecular targets for nutrients involved with cancer prevention. Nutr. Cancer 2001, 41, 1-16.
14. National Institutes of Health/Office of Dietary Supplements. Federal Register 2004, 69, 55821-55822.
15. Mann, C. D.; Neal, C. P.; Garcea, G.; Manson, M. M.; Dennison, A. R.; Berry, D. P. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur. J. Cancer Prev. 2009, 18, 13-25.
16. Elson, C. E. Supression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. J. Nutr. 1995, 125, 1666s-1672s.
17. Mo, H.; Elson, C. E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 2004, 229, 567-585.
18. Goldstein, J. L.; Brown, M. S. Regulation of the mevalonate pathway. Nature 1990, 343, 425-430.
19. Gregg, R. G.; Davidson, M.; Wilce, P. A. Cholesterol synthesis and HMG-CoA reductase activity during hepatocarcinogenesis in rats. Int. J. Biochem. 1986, 18, 389-393.
20. Siperstein, M. D. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J. Lipid. Res. 1984, 25, 1462-1468.
21. Moreno, F. S.; Rossiello, M. R.; Manjeshwar, S.; Nath, R.; Rao, P. M.; Rajalakshmi, S.; Sarma, D. S. Effect of beta-carotene on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver. Cancer Lett. 1995, 96, 201-208.
22. Espíndola, R. M.; Mazzantini, R. P.; Ong, T. P.; de Conti, A.; Heidor, R.; Moreno, F. S. Geranylgeraniol and β-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-KB activation. Carcinogenesis 2005, 26, 1091-1099.
23. Ong, T. P.; Heidor, R.; de Conti, A.; Dagli, M. L.; Moreno, F. S. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMG-CoA reductase. Carcinogenesis 2006, 27, 1194-1203.
24. Cardozo, M. T.; de Conti, A.; Ong, T. P.; Scolastici, C.; Purgatto, E.; Horst, M. A.; Bassoli, B. K.; Moreno, F. S. Chemopreventive effects of β-ionone and geraniol during rat hepatocarcinogenesis promotion: distinct actions on cell proliferation, apoptosis, HMG-CoA reductase, and RhoA. J. Nutr. Biochem. 2011, 22, 130-135.
25. Kurahashi, N.; Inoue, M.; Iwasaki, M.; Tanaka, Y.; Mizokami, M.; Tsugane, S. Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan. Br. J. Cancer 2009, 100, 181-184.
26. Polesel, J.; Talamini, R.; Montella, M.; Maso, L. D.; Crovatto, M.; Parpinel, M.; Izzo, F.; Tommasi, L. G.; Serraino, D.; La Vecchia, C.; Franceschi, S. Nutrients intake and the risk of hepatocellular carcinoma in Italy. Eur. J. Cancer 2007, 43, 2381-2387.
27. The Tocopherol, Beta-Carotene Cancer Prevention Study Group: the effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029-1035.
28. Omenn, G. S.; Goodman, G. E.; Thornquist, M. D.; Balmes, J.; Cullen, M. R.; Glass, A.; Keogh, J. P.; Meyskens, F. L.; Valanis, B.; Williams, J. H.; Barnhart, S.; Hammar, S. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1150-1155.
29. Moreno, F. S.; Rizzi, M. B.; Dagli, M. L.; Penteado, M. V. Inhibitory effects of β-carotene on preneoplastic lesions induced in Wistar rats by the resistant hepatocyte model. Carcinogenesis 1991, 12, 1817-1822.
30. Rizzi, M. B.; Dagli, M. L.; Jordão, A. A. Jr.; Penteado, M. V.; Moreno, F. S. β-Carotene inhibits persistent and stimulates remodeling gamma-GT positive preneoplastic lesions during early promotion of hepatocarcinogenesis. Int. J. Vitam. Nutr. Res. 1997, 67, 415-422.
31. De Luca, L. M.; Ross, S. A. β-Carotene increases lung cancer incidence in cigarette smokers. Nutr. Rev. 1996, 54, 178-180.
32. Pan, M. H.; Ho, C.T. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 2008, 37, 2558-2574.
33. Lee, K. W.; Bode, A. M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer 2011, 11, 211-218.
34. Hodek, P.; Krízková, J.; Burdová, K.; Sulc, M.; Kizek, R.; Hudecek, J.; Stiborová, M. Chemopreventive compounds-view from the other side. Chem. Biol. Interact. 2009, 180, 1-9.
35. Moreno, F. S.; Wu, T.-S.; Penteado, M. V.; Rizzi, M. B.; Jordão Júnior, A. A.; Almeida-Muradian, L. B.; Dagli, M. L. A comparison of β-carotene and vitamin A effects on a hepatocarcinogenesis model. Int. J. Vitam. Nutr. Res. 1995, 65, 87-94.
36. Dagli, M. L. Z.; Guerra, J. L.; Sinhorini, L.; Wu, T.-S.; Rizzi, M. B. S. L.; Penteado, M. V.; Moreno, F. S. β-Carotene reduces the ductular (oval) cell reaction in the liver of Wistar rats submitted to the resistant hepatocyte model of carcinogenesis. Pathology 1998, 30, 259-266.
37. de Almeida Vasconcelos Fonseca, E. M.; Chagas, C. E.; Mazzantini, R. P.; Heidor, R.; Ong, T. P.; Moreno, F. S. All-trans and 9-cis retinoic acids, retinol and β-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis 2005, 26, 1940-1946.
38. Sampaio, A. R.; Chagas, C. E.; Ong, T. P.; Moreno, F. S. Vitamin A and β-carotene inhibitory effect during 1, 2-dimethylhydrazine induced hepatocarcinogenesis potentiated by 5-azacytidine. Food Chem. Toxicol. 2007, 45, 563-567.
39. Solt, D. T.; Farber, E. New principle for the analysis of chemical carcinogenesis. Nature 1976, 263, 702-703.
40. Farber, E.; Sarma, D. S. Hepatocarcinogenesis: a dynamic cellular perspective. Lab. Invest. 1987, 56, 4-22.
41. Semple-Roberts, E.; Hayes, M. A.; Armstrong, D.; Becker, R. A.; Racz, W. J.; Farber, E. Alternative methods of selecting rat hepatocellular nodules resistant to 2-acetylaminofluorene. Int. J. Cancer 1987, 40, 643-645.
42. Tsuda, H.; Lee, G.; Farber, E. Induction of resistant hepatocytes as a new principle for a possible short term in vivo test for carcinogens. Cancer Res. 1980, 40, 1157-1164.
43. Sarkar, A; Mukherjee, B; Chatterjee, M. Inhibitory effect of β-carotene on 2-acetylaminofluorene-induced hepatocarcinogenesis in rat: reflection in hepatic drug metabolism. Carcinogenesis 1994, 15, 1055-1060.
44. Sarkar, A.; Bishayee, A.; Chatterjee, M. β-Carotene prevents lipid peroxidation and red blood cell membrane protein damage in experimental hepatocarcinogenesis. Cancer Biochem. Biophys. 1995, 15, 111-125.
45. Bishayee, A.; Sarkar, A.; Chatterjee, M. Further evidence for chemopreventive potential of β-carotene against experimental carcinogenesis: diethylnitrosamine-initiated and phenobarbitalpromoted hepatocarcinogenesis is prevented more effectively by β-carotene than by retinoic acid. Nutr. Cancer 2000, 37, 89-98.
46. Sarkar, A.; Mukherjee, B.; Chatterjee, M. Inhibition of 3'-methyl-4-dimethylaminoazobenzene-induced hepatocarcinogenesis in rat by dietary beta-carotene: changes in hepatic anti-oxidant defense enzyme levels. Int. J. Cancer 1995 61, 799-805.
47. Tsuda, H.; Uehara, N.; Iwahori, Y.; Asamoto, M.; Iigo, M.; Nagao, M.; Matsumoto, K.; Ito, M.; Hirono, I. Chemopreventive effects of β-carotene, α-tocopherol and five naturally occurring antioxidants on initiation of hepatocarcinogenesis by 2-amino-3-methylimidazo[4,5-f]quinoline in the rat. Jpn. J. Cancer Res. 1994, 85, 1214-1219.
48. He, Y.; Root, M. M.; Parker, R. S.; Campbell, T. C. Effects of carotenoid-rich food extracts on the development of preneoplastic lesions in rat liver and on in vivo and in vitro antioxidant status. Nutr. Cancer 1997, 27, 238-244.
49. Gradelet, S.; Astorg, P.; Le Bon, A. M.; Bergès, R.; Suschetet, M. Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1a inducers. Cancer Lett. 1997, 114, 221-223.
50. Sadek, I. A.; Hayat, L. G. Initiation and post-initiation chemopreventive effects of β-carotene in toad liver carcinogenesis. Histol. Histopathol. 1996, 11, 357-360.
51. Astorg, P.; Gradelet, S.; Bergès, R.; Suschetet, M. No Evidence for an inhibitory effect of β-carotene or of canthaxanthin on the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr. Cancer 1996, 25, 27-34.
52. Moreno, F. S.; Wu, S.-T.; Naves, M. M.; Silveira, E. R.; Oloris, S. C.; da Costa, M. A.; Dagli, M. L.; Ong, T. P. Inhibitory effects of β-carotene and vitamin A during the progression phase of hepatocarcinogenesis involve inhibition of cell proliferation but not alterations in DNA methylation. Nutr. Cancer 2002, 44, 80-88.
53. Astorg, P.; Gradelet, S.; Leclerc, J.; Siess, M-H. Effects of provitamin A or non-provitamin A carotenoids on liver xenobioticmetabolizing enzymes in mice. Nutr. Cancer 1997, 27, 245-249.
54. Naves, M. M. V.; Moreno, F. S. β-Carotene and cancer chemoprevention: from epidemiological associations to cellular mechanisms of action. Nutr. Res. 1998, 18, 1807-1824.
55. Farber, E.; Rubin, H. Cellular adaptation in the origin and development of cancer. Cancer Res. 1991, 51, 2751-2761.
56. Wood, G. A.; Sarma, D. S.; Archer, M. C. Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis 1999, 20, 1169-1175.
57. Feo, F.; Pascale, R. M.; Simile, M. M.; De Miglio, M. R.; Muroni, M. R.; Calvisi, D. Genetic alterations in liver carcinogenesis: Implications for new preventive and therapeutic strategies. Crit. Rev. Oncog. 2000, 11, 19-62.
58. Feo, F.; De Miglio, M. R.; Simile, M. M.; Muroni, M. R.; Calvisi, D. F.; Frau, M.; Pascale, R. M. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim. Biophys. Acta 2006, 1765, 126-147.
59. Schulte-Hermann, R.; Timmermann-Trosiener, L.; Barthel, G.; Bursch, W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res. 1990, 50, 5127-5135.
60. Wójcik, M.; Bobowiec, R.; Martelli, F. Effect of carotenoids on in vitro proliferation and differentiation of oval cells during neoplastic and non-neoplastic liver injuries in rats. J. Physiol. Pharmacol. 2008, 59, 203-213.
61. Naves, M. M.; Silveira, E. R.; Dagli, M. L.; Moreno, F. S. Effects of β-carotene and vitamin A on oval cell proliferation and connexin 43 expression during hepatic differentiation in the rat. J. Nutr. Biochem. 2001, 12, 685-692.
62. Thorgeirsson, S. S. Hepatic stem cells in liver regeneration. FASEB J. 1996, 10, 1249-1256.
63. Zhang, M.; Thorgeirsson, S. S. Modulation of connexins during differentiation of oval cells into hepatocytes. Exp. Cell Res. 1994, 213, 37-42.
64. Hixson, D. C.; Chapman, L.; McBride, A.; Faris, R.; Yang, L. Antigenic phenotypes common to rat oval cells, primary hepatocellular carcinomas and developing bile ducts. Carcinogenesis 1997, 18, 1169-1175.
65. Guest, I.; Ilic, Z.; Sell, S. Age dependence of oval cell responses and bile duct carcinomas in male Fischer 344 rats fed a cyclic choline-deficient, ethionine-supplemented diet. Hepatology 2010, 52, 1750-1757.
66. Nowell, P. C. Clonal evolution of tumor-cell populations. Science 1976, 194, 123-128.
67. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
68. Marquardt, J. U.; Factor, V. M.; Thorgeirsson, S. S. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J. Hepatol. 2010, 53, 568-577.
69. Vinken, M.; Henkens, T.; De Rop, E.; Fraczek, J.; Vanhaecke, T.; Rogiers, V. Biology and pathobiology of gap junctional channels in hepatocytes. Hepatology 2008, 47, 1077-1088.
70. Bertram, J. S.; Vine, A. L. Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim. Biophys. Acta. 2005, 1740, 170-178.
71. Rühl, R.; Sczech, R.; Landes, N.; Pfluger, P.; Kluth, D.; Schweigert, F. J. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur. J. Nutr. 2004, 43, 336-343.
72. Murakoshi, M.; Nishino, H.; Satomi, Y.; Takayasu, J.; Hasegawa, T.; Tokuda, H.; Iwashima, A.; Okuzumi, J.; Okabe, H.; Kitano, H.; Iwasaki, R. Potent preventive action of α-carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by α-carotene than by β-carotene. Cancer Res. 1992, 52, 6583-6587.
73. Toledo, L. P.; Ong, T. P.; Pinho, A. L.; Jordão, Jr. A.A.; Vannucchi, H.; Moreno, F. S. Inhibitory effects of lutein and lycopene on placental glutathione S-transferase-positive preneoplastic lesions and DNA strand breakage induced in Wistar rats by the resistant hepatocyte model of hepatocarcinogenesis. Nutr. Cancer 2003, 47, 62-69.
74. Moreno, F. S.; Toledo, L. P.; de Conti, A.; Heidor, R.; Jordão, A. Jr.; Vannucchi, H.; Cardozo, M. T.; Ong, T. P. Lutein presents suppressing but not blocking chemopreventive activity during diethylnitrosamine-induced hepatocarcinogenesis and this involves inhibition of DNA damage. Chem. Biol. Interact. 2007, 168, 221-228.
75. Scolastici, C.; Lopes, G. A.; Barbisan, L. F.; Salvadori, D. M. Tomato oleoresin inhibits DNA damage but not diethylnitrosamineinduced rat hepatocarcinogenesis. Exp. Toxicol. Pathol. 2008, 60, 59-68.
76. Gradelet, S.; Le Bon, A. M.; Berges, R.; Suschetet, M.; Astorg, P. Dietary carotenoids inhibit aflatoxin B1-induced liver preneoplastic foci and DNA damage in the rat: Role of the modulation of aflatoxin B1 metabolism. Carcinogenesis 1998, 19, 403-411.
77. Watanabe, S.; Kitade, Y.; Masaki, T.; Nishioka, M.; Satoh, K.; Nishino, H. Effects of lycopene and sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr. Cancer 2001, 39, 96-101.
78. Van Breemen, R. B.; Pajkovic, N. Multitargeted therapy of cancer by lycopene. Cancer Lett. 2008, 269, 339-351.
79. Nishino, H. Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture: recent results. Recent Results Cancer Res. 2007, 174, 67-71.
80. Astorg, P.; Gradelet, S.; Bergès, R.; Suschetet, M. Dietary lycopene decreases the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr. Cancer. 1997, 29, 60-68.
81. Nishino, H. Cancer prevention by natural carotenoids. J. Cell. Biochem. Suppl. 1997, 27, 86-91.
82. Tharappel, J. C.; Lehmler, H. J.; Srinivasan, C.; Robertson, L. W.; Spear, B. T.; Glauert, H. P. Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3',4,4'-tetrachlorobiphenyl (PCB-77). Food Chem. Toxicol. 2008, 46, 3467-3474.
83. Wang, Y.; Ausman, L. M.; Greenberg, A. S.; Russell, R. M.; Wang, X. D. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int. J. Cancer 2010, 126, 1788-1796.
84. Breinholt, V. M.; Molck, A. M.; Svendsen, G. W.; Daneshvar, B.; Vinggaard, A. M.; Poulsen, M.; Dragsted, L. O. Effects of dietary antioxidants and 2-amino-3-methylimidazo[4,5-f]-quinoline (IQ) on preneoplastic lesions and on oxidative damage, hormonal status, and detoxification capacity in the rat. Food Chem. Toxicol. 2003, 41, 1315-1323.
85. Park, Y. O.; Hwang, E. S.; Moon, T. W. The effect of lycopene on cell growth and oxidative DNA damage of Hep3b human hepatoma cells. Biofactors 2005, 23, 129-139.
86. Hwang, E. S.; Lee, H. J. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp. Biol. Med. 2006, 231, 322-327.
87. Huang, C. S.; Shih, M. K.; Chuang, C. H.; Hu, M. L. Lycopene inhibits cell migration and invasion and upregulates Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J. Nutr. 2005, 135, 2119-2123.
88. Palozza, P.; Colangelo, M.; Simone, R.; Catalano, A.; Boninsegna, A.; Lanza, P.; Monego, G.; Ranelletti, F. O. Lycopene induces cell growth inhibition by altering mevalonate pathway and ras signaling in cancer cell lines. Carcinogenesis 2010, 31, 1813-1821.
89. Shiota, G.; Tsuchiya, H.; Hoshikawa, Y. The liver as a target organ of retinoids. Hepatol. Res. 2006, 36, 248-254.
90. Silveira, E. R.; Naves, M. M. V.; Vannucchi, H.; Jordão, A. A. Jr.; Dagli, M. L. Z.; Moreno, F. S. Vitamin A and all-trans and 9-cis retinoic acids inhibit cell proliferation during the progression phase of hepatocarcinogenesis in Wistar rats. Nutr. Cancer 2001, 39, 244-251.
91. Yuan, J. M.; Gao, Y. T.; Ong, C. N.; Ross, R. K.; Yu, M. C. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2006, 98, 482-490.
92. nd ed.; Raven Press Ltd. New York, 1994, pp. 597-630.
93. Lotan, R. Retinoids in cancer chemoprevention. FASEB J. 1996, 10, 1031-1039.
94. Mack, D. O.; Reed, V. L.; Smith, L. D. Retinyl acetate inhibition of 3'-methyl-4-dimethyl-aminoazobenzene induced hepatic neoplasia. Int. J. Biochem. 1990, 22, 359-365.
95. Berberian, I.; Chen, L. C.; Robinson, F. R.; Glauert, H. P.; Chow, C. K.; Robertson, L. W. Effect of dietary retinyl palmitate on the promotion of altered hepatic foci by 3,3',4,4'-tetrachlorobiphenyl and 2,2',4,4',5,5'-hexachlorobiphenyl in rats initiated with diethylnitrosamine. Carcinogenesis 1995, 16, 393-398.
96. Newberne, P. M.; Suphakarn, V. Preventive role of vitamin A in colon carcinogenesis in rats. Cancer 1977, 40, 2553-2556.
97. Ohkawa, K.; Abe, T.; Hatano, T.; Takizawa, N.; Yamada, K.; Takada, K. The facilitated effect of retinol on rat hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene. Carcinogenesis 1991, 12, 2357-2360.
98. Tamura, K.; Nakae, D.; Horiguchi, K.; Akai, H.; Kobayashi, Y.; Andoh, N.; Satoh, H.; Denda, A.; Tsujiuchi, T.; Yoshiji, H.; Konishi, Y. Inhibition by N-(4-hydroxyphenyl) retinamide and alltrans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental formpositive lesions in the livers of rats. Carcinogenesis 1997, 18, 2133-2141.
99. Baba, M.; Ishi, H.; Yamamoto, R.; Tatsuta, M. Inhibition by retinoic acid of hepatocarcinogenesis induced by nnitrosomorpholine and of expression of myc oncogene protein in Sprague-Dawley rats. Int. J. Cancer 1991, 49, 467-470.
100. Daoud, A. H.; Griffin, A. C. Effect of retinoic acid, butylated hydroxytoluene, selenium and sorbic acid on azo-dye hepatocarcinogenesis. Cancer Lett. 1980, 9, 299-304.
101. Maiorana, A.; Gullino, P. M. Effect of retinyl acetate on the incidence of mammary carcinomas and hepatomas in mice. J. Natl. Cancer Inst. 1980, 64, 655-663.
102. McCormick, D. L.; Hollister, J. L.; Bagg, B. J.; Long, R. E. Enhancement of murine hepatocarcinogenesis by all-trans-retinoic acid and two synthetic retinamides. Carcinogenesis 1990, 11, 1605-1609.
103. Calvisi, D. F.; Simile, M. M.; Ladu, S.; Pellegrino, R.; De Murtas, V.; Pinna, F.; Tomasi, M. L.; Frau, M.; Virdis, P.; De Miglio, M. R.; Muroni, M. R.; Pascale, R. M.; Feo, F. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int. J. Cancer 2007, 121, 2410-2420.
104. Chagas, C. E. A.; Bassoli, B. K.; Souza, C. A. S.; Jordão, Jr. A.; Paiva, S. A. R.; Dagli, M. L. Z.; Ong, T. P.; Moreno, F. S. Folic acid supplementation during early hepatocarcinogenesis: cellular and molecular effects. Int. J. Cancer 2011, 129, 2073-2082.
105. Ong, T.P.; Moreno, F.S.; Ross, S.A. Targeting the epigenome with bioactive food components for cancer prevention. J. Nutrigenet. Nutrigenomics 2011, 5, 275-292.
106. Vine, A. L.; Bertram, J. S. Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs. Nutr. Cancer 2005, 52, 105-113.
107. Mangelsdorf, D. J. Vitamin A receptors. Nutr. Rev. 1994, 52, S32-S44.
108. Mangelsdorf, D. J.; Evans, R. M. The RXR heterodimers and orphan receptors. Cell 1995, 83, 841-850.
109. Osada, S.; Naganawa, A.; Misonou, M.; Tsuchiya, S.; Tamba, S.; Okuno, Y.; Nishikawa, J.; Satoh, K.; Imagawa, M.; Tsujimoto, G.; Sugimoto, Y.; Nishihara, T. Altered gene expression of transcriptional regulatory factors in tumor marker-positive cells during chemically induced hepatocarcinogenesis. Toxicol. Lett. 2006, 167, 106-113.
110. Ando, N.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Expression of retinoid X receptor α is decreased in 3'-methyl-4-dimethylaminoazobenzeneinduced hepatocellular carcinoma in rats. Oncol. Rep. 2007, 18, 879-884.
111. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Tsurumi, H.; Moriwaki, H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res. 2008, 14, 2806-2812.
112. Kanamori, T.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Tsurumi, H.; Kojima, S.; Moriwaki, H. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci. 2007, 98, 431-437.
113. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Yasuda, Y.; Tsurumi, H.; Moriwaki, H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009, 285, 210-217.
114. De Conti, A.; Kuroiwa-Trzmielina, J.; Horst, M. A.; Bassoli, B. K.; Chagas, C. E.; Purgatto, E.; Cavalher, F. P.; Camargo, A. A.; Jordão Junior, A. A.; Vannucchi, H.; Scolastici, C.; Ong, T. P.; Moreno, F. S. Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. J. Nutr. Biochem. 2011, 23, 860-866.
115. Yan, T. D.; Wu, H.; Zhang, H. P.; Lu, N.; Ye, P.; Yu, F. H.; Zhou, H.; Li, W. G.; Cao, X.; Lin, Y. Y.; He, J. Y.; Gao, W. W.; Zhao, Y.; Xie, L.; Chen, J. B.; Zhang, X. K.; Zeng, J. Z. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 2010, 70, 2285-2295.
116. Mills, J. J. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res. 1995, 55, 979-983.
117. Kaji, I.; Tatsuta, M.; Iishi, H.; Baba, M.; Inoue, A.; Kasugai, H. Inhibition by D-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(Ras) plasma membrane association. Int. J. Cancer 2009, 93, 441-444.
118. Giri, R. K.; Parija, T.; Das, B. R. D-Limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-Jun and c-Myc. Oncol. Rep. 1999, 6, 1123-1127.
119. Wiseman, D. A.; Werner, S. R.; Crowell, P. L. Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J. Pharmacol. Exp. Ther. 2007, 320, 1163-1170.
120. Monte, M. J.; Fernandez-Tagarro, M.; Macias, R. I.; Jiménez, F.; Gonzalez-San Martín, F.; Marin, J. J. Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. 2005, 109, 199-207.
121. O'Brien, M. L.; Rangwala, S. M.; Henry, K. W.; Weinberger, C.; Crick, D. C.; Waechter, C. J.; Feller, D. R.; Noonan, D. J. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis 1996, 17, 185-190.
122. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D. D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67, 863-867.
123. Zhang, Y.; Gong, W.; Dai, S.; Huang, G.; Shen, X.; Gao, M.; Xu, Z.; Zeng, Y.; He, F. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol. Cancer Res. 2012, Mar 23. doi: 10.1158/1541-7786.MCR-11-0473.
124. Scolastici, C.; Ong, T. P.; Moreno, F. S. Squalene does not exhibit a chemopreventive activity and increases plasma cholesterol in a Wistar rat hepatocarcinogenesis model. Nutr. Cancer 2004, 50, 101-109.
125. Shidoji, Y.; Ogawa, H. Natural occurrence of cancer preventive geranylgeranoic acid in medicinal herbs. J. Lipid Res. 2004, 45, 1092-1103.
126. Trosko, J. E. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed. Pharmacother. 2005, 59, S326-S331.
127. Vasiliev, J. M.; Omelchenko, T.; Gelfand, I. M.; Feder, H. H.; Bonder, E. M. Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: a link to the mechanism of cancer dissemination. Proc. Natl. Acad. Sci. USA 2004, 101, 12526-12530.
128. Grise, F.; Bidaud, A.; Moreau, V. Rho GTPases in hepatocellular carcinoma. Biochem. Biophys. Acta 2009, 1795, 137-151.
129. Holstin, S. A.; Hohl, R. J. Monoterpene regulation of Ras and Rasrelated protein expression. J. Lipid Res. 2003, 44, 1209-1215.
130. Li, E.; Liu, L.; Tupper, J. C.; Bannerman, D. D.; Winn, R. K.; Sebti, S. M.; Hamilton, A. D.; Harlan, J. M. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 2002, 277, 15309-15316.
131. Doroshow, J. H.; Parchment, R. E. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin. Cancer Res. 2008, 14, 3658-3663.
132. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H. The statistics of phase 0 trials. Stat. Med. 2010, 29, 1072-1076.